RE:RE:RE:RE:RE:RE:RE:RE:⚡⚡⚡Facts: GRAIL Confirms Q2 2021 Introduction of Gallerifrewil11 wrote: Yes Aristotle can be massive , but they have to market it properly and sign the right partner agreements , Colonsentry is the best for early detection , what happened.
Yes Colonsentry stands as a good example of a medical tech which has been largely unsuccessful due to the lack of proper marketing. There was really no advertising campaign with it other than social media and would be clients were simply unaware. People don't google SZLS because they haven't heard of it to do so - there has to be public awareness and eventually acceptance for a product to flourish and the hope is that Aristotle will benefit from that. Existing covid clients, Ichor and Mercer will go a long way in this regard but we still need more - fortunately we have the funds behind us this time and the promise of new and significant partners should rectify this. Its a tough market out there to break into, particularly with covid as a diversion, however many potential clients have seen cancer go undetected over the past year and the hope is that they will pony up the dollars for the test of their choice - luckily there has been a surge in household savings during the covid lockdowns to help out with that. Healthcare will always be a primary concern and cancer is at the forefront - really Aristotle is coming out at a great time to capitalize and with the proper awareness, Colonsentry might gain popularity along with the other tests.